|
|
Blood, 15 August 2004, Vol. 104, No. 4, pp. 1159-1165.
Prepublished online as a Blood First Edition Paper on May 6, 2004; DOI 10.1182/blood-2003-11-3811.
 Previous Article | Table of Contents | Next Article 
NEOPLASIA
Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression
Shaji Kumar,
Thomas E. Witzig,
Michael Timm,
Jessica Haug,
Linda Wellik,
Teresa K. Kimlinger,
Philip R. Greipp, and
S. Vincent Rajkumar
From the Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN.
We compared the angiogenic potential of bone marrow plasma and the expression of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and their receptors on plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and newly diagnosed multiple myeloma (NMM). Cytokine and cytokine-receptor expression was studied by bone marrow immunohistochemistry, quantitative reverse transcription-polymerase chain reaction (RT-PCR) on sorted plasma cells, and quantitative Western blot analysis. Bone marrow angiogenic potential was studied using a human in vitro angiogenesis assay. The expression levels of VEGF, bFGF, and their receptors were similar among MGUS, SMM, and NMM. Sixty-one percent of NMM samples stimulated angiogenesis in the in vitro angiogenesis assay compared with SMM (0%) and MGUS (7%) (P < .001). Importantly, 63% of MGUS samples inhibited angiogenesis compared with SMM (43%) and NMM (4%) (P < .001). The inhibitory activity was heat stable, not overcome by the addition of VEGF, and corresponded to a molecular weight below 10 kd by size-exclusion chromatography. Our results suggest that increasing angiogenesis from MGUS to NMM is, at least in part, explained by increasing tumor burden rather than increased expression of VEGF/bFGF by individual plasma cells. The active inhibition of angiogenesis in MGUS is lost with progression, and the angiogenic switch from MGUS to NMM may involve a loss of inhibitory activity. (Blood. 2004; 104:1159-1165)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Population dynamics and clonal dominance in tumors?
- Eva A. Turley and James B. McCarthy
Blood 2004 104: 909-910.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
D. Hose, J. Moreaux, T. Meissner, A. Seckinger, H. Goldschmidt, A. Benner, K. Mahtouk, J. Hillengass, T. Reme, J. De Vos, et al.
Induction of angiogenesis by normal and malignant plasma cells
Blood,
July 2, 2009;
114(1):
128 - 143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Hillengass, C. Zechmann, T. Bauerle, B. Wagner-Gund, C. Heiss, A. Benner, A. Ho, K. Neben, D. Hose, H.-U. Kauczor, et al.
Dynamic Contrast-Enhanced Magnetic Resonance Imaging Identifies a Subgroup of Patients with Asymptomatic Monoclonal Plasma Cell Disease and Pathologic Microcirculation
Clin. Cancer Res.,
May 1, 2009;
15(9):
3118 - 3125.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. L. Coluccia, T. Cirulli, P. Neri, D. Mangieri, M. C. Colanardi, A. Gnoni, N. Di Renzo, F. Dammacco, P. Tassone, D. Ribatti, et al.
Validation of PDGFR{beta} and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib
Blood,
August 15, 2008;
112(4):
1346 - 1356.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Colla, S. Tagliaferri, F. Morandi, P. Lunghi, G. Donofrio, D. Martorana, C. Mancini, M. Lazzaretti, L. Mazzera, L. Ravanetti, et al.
The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 {alpha} (HIF-1{alpha}) activity: involvement in myeloma-induced angiogenesis
Blood,
December 15, 2007;
110(13):
4464 - 4475.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Tanaka, M. Abe, M. Hiasa, A. Oda, H. Amou, A. Nakano, K. Takeuchi, K. Kitazoe, S. Kido, D. Inoue, et al.
Myeloma Cell-Osteoclast Interaction Enhances Angiogenesis Together with Bone Resorption: A Role for Vascular Endothelial Cell Growth Factor and Osteopontin
Clin. Cancer Res.,
February 1, 2007;
13(3):
816 - 823.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. G. Richardson, T. Hideshima, and K. C. Anderson
Plasma cell dyscrasias
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
298 - 327.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. K. Martin, A. L. Dewar, A. N. Farrugia, N. Horvath, S. Gronthos, L. B. To, and A. C.W. Zannettino
Tumor Angiogenesis Is Associated with Plasma Levels of Stromal-Derived Factor-1{alpha} in Patients with Multiple Myeloma
Clin. Cancer Res.,
December 1, 2006;
12(23):
6973 - 6977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Vacca, C. Scavelli, G. Serini, G. Di Pietro, T. Cirulli, F. Merchionne, D. Ribatti, F. Bussolino, D. Guidolin, G. Piaggio, et al.
Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma
Blood,
September 1, 2006;
108(5):
1661 - 1667.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. Chng, S. A. Van Wier, G. J. Ahmann, J. M. Winkler, S. M. Jalal, P. L. Bergsagel, M. Chesi, M. C. Trendle, M. M. Oken, E. Blood, et al.
A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS
Blood,
September 15, 2005;
106(6):
2156 - 2161.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Zhou, H. Zhou, P. J. Walian, and B. K. Jap
CD147 is a regulatory subunit of the {gamma}-secretase complex in Alzheimer's disease amyloid {beta}-peptide production
PNAS,
May 24, 2005;
102(21):
7499 - 7504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. V. Rajkumar
MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management
Hematology,
January 1, 2005;
2005(1):
340 - 345.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
